• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲基化砷代谢产物与早幼粒细胞白血病(PML)蛋白结合,但不诱导细胞分化和早幼粒细胞白血病锌指蛋白-维甲酸受体α(PML-RARα)蛋白降解。

Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.

作者信息

Wang Qian Qian, Zhou Xin Yi, Zhang Yan Fang, Bu Na, Zhou Jin, Cao Feng Lin, Naranmandura Hua

机构信息

Department of Toxicology, School of Medicine and Public Health, Zhejiang University, Hangzhou 310058, China.

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.

出版信息

Oncotarget. 2015 Sep 22;6(28):25646-59. doi: 10.18632/oncotarget.4662.

DOI:10.18632/oncotarget.4662
PMID:26213848
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4694856/
Abstract

Arsenic trioxide (As2O3) is one of the most effective therapeutic agents used for patients with acute promyelocytic leukemia (APL). The probable explanation for As2O3-induced cell differentiation is the direct targeting of PML-RARα oncoprotein by As2O3, which results in initiation of PML-RARα degradation. However, after injection, As2O3 is rapidly methylated in body to different intermediate metabolites such as trivalent monomethylarsonous acid (MMA(III)) and dimethylarsinous acid (DMA(III)), therefore, it remains unknown that which arsenic specie is actually responsible for the therapeutic effects against APL. Here we have shown the role of As2O3 (as iAs(III)) and its intermediate metabolites (i.e., MMA(III)/DMA(III)) in NB4 cells. Inorganic iAs(III) predominantly showed induction of cell differentiation, while MMA(III) and DMA(III) specifically showed to induce mitochondria and endoplasmic reticulum-mediated apoptosis, respectively. On the other hand, in contrast to iAs(III), MMA(III) showed stronger binding affinity for ring domain of PML recombinant protein, however, could not induce PML protein SUMOylation and ubiquitin/proteasome degradation. In summary, our results suggest that the binding of arsenicals to the ring domain of PML proteins is not associated with the degradation of PML-RARα fusion protein. Moreover, methylated arsenicals can efficiently lead to cellular apoptosis, however, they are incapable of inducing NB4 cell differentiation.

摘要

三氧化二砷(As2O3)是用于急性早幼粒细胞白血病(APL)患者的最有效治疗药物之一。As2O3诱导细胞分化的可能解释是As2O3直接靶向PML-RARα癌蛋白,从而导致PML-RARα降解的启动。然而,注射后,As2O3在体内迅速甲基化形成不同的中间代谢产物,如三价一甲基胂酸(MMA(III))和二甲基胂酸(DMA(III)),因此,究竟哪种砷物种实际上对APL的治疗效果负责仍不清楚。在这里,我们展示了As2O3(以iAs(III)形式)及其中间代谢产物(即MMA(III)/DMA(III))在NB4细胞中的作用。无机iAs(III)主要表现出诱导细胞分化,而MMA(III)和DMA(III)分别特异性地表现出诱导线粒体和内质网介导的凋亡。另一方面,与iAs(III)相反,MMA(III)对PML重组蛋白的环结构域显示出更强的结合亲和力,然而,不能诱导PML蛋白的SUMO化和泛素/蛋白酶体降解。总之,我们的结果表明,砷化合物与PML蛋白环结构域的结合与PML-RARα融合蛋白的降解无关。此外,甲基化的砷化合物可以有效地导致细胞凋亡,然而,它们不能诱导NB4细胞分化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52d3/4694856/4e65fcb6a12a/oncotarget-06-25646-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52d3/4694856/3a09cc5a5bb5/oncotarget-06-25646-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52d3/4694856/0e8ae555c671/oncotarget-06-25646-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52d3/4694856/76bb71c0bc45/oncotarget-06-25646-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52d3/4694856/76dabc8d73a4/oncotarget-06-25646-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52d3/4694856/1923dca0cb1a/oncotarget-06-25646-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52d3/4694856/4e65fcb6a12a/oncotarget-06-25646-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52d3/4694856/3a09cc5a5bb5/oncotarget-06-25646-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52d3/4694856/0e8ae555c671/oncotarget-06-25646-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52d3/4694856/76bb71c0bc45/oncotarget-06-25646-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52d3/4694856/76dabc8d73a4/oncotarget-06-25646-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52d3/4694856/1923dca0cb1a/oncotarget-06-25646-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52d3/4694856/4e65fcb6a12a/oncotarget-06-25646-g006.jpg

相似文献

1
Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.甲基化砷代谢产物与早幼粒细胞白血病(PML)蛋白结合,但不诱导细胞分化和早幼粒细胞白血病锌指蛋白-维甲酸受体α(PML-RARα)蛋白降解。
Oncotarget. 2015 Sep 22;6(28):25646-59. doi: 10.18632/oncotarget.4662.
2
Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells.三氧化二砷的甲基化代谢产物在白血病和淋巴瘤细胞中作为凋亡诱导剂比三氧化二砷更有效,但不是分化诱导剂。
Cancer Res. 2003 Apr 15;63(8):1853-9.
3
Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.三氧化二砷通过直接结合 PML 来控制 PML-RARα 癌蛋白的命运。
Science. 2010 Apr 9;328(5975):240-3. doi: 10.1126/science.1183424.
4
Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.三氧化二砷和美拉胂醇可诱导髓系白血病细胞系发生程序性细胞死亡,且以一种独立于早幼粒细胞白血病蛋白(PML)和早幼粒细胞白血病蛋白-维甲酸受体α(PML-RARα)的方式发挥作用。
Blood. 1998 Sep 1;92(5):1497-504.
5
Metabolism of arsenic trioxide in acute promyelocytic leukemia cells.三氧化二砷在急性早幼粒细胞白血病细胞中的代谢
J Cell Biochem. 2014 Oct;115(10):1729-39. doi: 10.1002/jcb.24838.
6
TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.TRIB3 通过稳定癌蛋白 PML-RARα 和抑制 p53 介导的衰老促进 APL 进展。
Cancer Cell. 2017 May 8;31(5):697-710.e7. doi: 10.1016/j.ccell.2017.04.006.
7
Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.缺氧模拟剂与三氧化二砷诱导急性早幼粒细胞白血病细胞生长停滞和细胞分化的选择性刺激作用
Haematologica. 2005 Dec;90(12):1607-16.
8
PCGF2 negatively regulates arsenic trioxide-induced PML-RARA protein degradation via UBE2I inhibition in NB4 cells.在NB4细胞中,PCGF2通过抑制UBE2I负向调节三氧化二砷诱导的PML-RARA蛋白降解。
Biochim Biophys Acta. 2016 Jul;1863(7 Pt A):1499-509. doi: 10.1016/j.bbamcr.2016.03.019. Epub 2016 Mar 24.
9
Importance of ERK activation in As2O3-induced differentiation and promyelocytic leukemia nuclear bodies formation in neuroblastoma cells.ERK 激活在三氧化二砷诱导神经母细胞瘤细胞分化和早幼粒细胞白血病核小体形成中的重要性。
Pharmacol Res. 2013 Nov;77:11-21. doi: 10.1016/j.phrs.2013.08.005. Epub 2013 Sep 1.
10
Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.在一名对维甲酸(RA)治疗耐药的t(11;17)(q23;q21)急性早幼粒细胞白血病(APL)患者中,维甲酸而非三氧化二砷可降解PLZF/RARα融合蛋白,且不会诱导终末分化或凋亡。
Oncogene. 1999 Jan 28;18(4):1113-8. doi: 10.1038/sj.onc.1202414.

引用本文的文献

1
ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL.ALLG APML5:急性早幼粒细胞白血病巩固治疗期间口服三氧化二砷的生物利用度和安全性。
Blood Adv. 2025 Mar 25;9(6):1476-1484. doi: 10.1182/bloodadvances.2024015397.
2
Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function.砷靶向 PML-RARA 癌蛋白的结构基础揭示了一个半胱氨酸变阻器,控制 PML 体的组装和功能。
Cancer Discov. 2023 Dec 12;13(12):2548-2565. doi: 10.1158/2159-8290.CD-23-0453.
3
Arsenic causing gallbladder cancer disease in Bihar.

本文引用的文献

1
Metabolism of arsenic trioxide in acute promyelocytic leukemia cells.三氧化二砷在急性早幼粒细胞白血病细胞中的代谢
J Cell Biochem. 2014 Oct;115(10):1729-39. doi: 10.1002/jcb.24838.
2
Curing APL through PML/RARA degradation by As2O3.通过三氧化二砷降解 PML/RARA 治疗早幼粒细胞白血病。
Trends Mol Med. 2012 Jan;18(1):36-42. doi: 10.1016/j.molmed.2011.10.001. Epub 2011 Nov 4.
3
Comparative toxicity of arsenic metabolites in human bladder cancer EJ-1 cells.砷代谢物在人膀胱癌 EJ-1 细胞中的比较毒性。
砷导致比哈尔邦的胆囊癌。
Sci Rep. 2023 Mar 14;13(1):4259. doi: 10.1038/s41598-023-30898-0.
4
The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases.口服三氧化二砷在急性早幼粒细胞白血病及其他疾病中的研发与临床应用
Pharmaceutics. 2022 Sep 14;14(9):1945. doi: 10.3390/pharmaceutics14091945.
5
Polymorphisms in arsenic (+ 3 oxidation state) methyltransferase (AS3MT) predict the occurrence of hyperleukocytosis and arsenic metabolism in APL patients treated with AsO.砷 (+3 氧化态) 甲基转移酶 (AS3MT) 中的多态性可预测接受 AsO 治疗的 APL 患者发生高白细胞血症和砷代谢的情况。
Arch Toxicol. 2020 Apr;94(4):1203-1213. doi: 10.1007/s00204-020-02686-6. Epub 2020 Feb 28.
6
[Involvement of PML proteins in treatment of acute promyelocytic leukemia with arsenic trioxide].[PML蛋白在三氧化二砷治疗急性早幼粒细胞白血病中的作用]
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2018 May 25;47(5):541-551. doi: 10.3785/j.issn.1008-9292.2018.10.15.
7
Phenylarsine Oxide Can Induce the Arsenite-Resistance Mutant PML Protein Solubility Changes.苯胂化氧可诱导抗亚砷酸盐突变型早幼粒细胞白血病(PML)蛋白的溶解性变化。
Int J Mol Sci. 2017 Jan 25;18(2):247. doi: 10.3390/ijms18020247.
8
Metabolism, toxicity and anticancer activities of arsenic compounds.砷化合物的代谢、毒性及抗癌活性
Oncotarget. 2017 Apr 4;8(14):23905-23926. doi: 10.18632/oncotarget.14733.
9
Monomethylarsonous acid, but not inorganic arsenic, is a mitochondria-specific toxicant in vascular smooth muscle cells.一甲基亚胂酸而非无机砷是血管平滑肌细胞中的一种线粒体特异性毒物。
Toxicol In Vitro. 2016 Sep;35:188-201. doi: 10.1016/j.tiv.2016.06.006. Epub 2016 Jun 17.
Chem Res Toxicol. 2011 Sep 19;24(9):1586-96. doi: 10.1021/tx200291p. Epub 2011 Aug 16.
4
Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.PML-RARA 中的错义突变是导致三氧化二砷治疗反应缺乏的关键因素。
Blood. 2011 Aug 11;118(6):1600-9. doi: 10.1182/blood-2011-01-329433. Epub 2011 May 25.
5
Arsenite interacts selectively with zinc finger proteins containing C3H1 or C4 motifs.砷剂与含有 C3H1 或 C4 基序的锌指蛋白选择性相互作用。
J Biol Chem. 2011 Jul 1;286(26):22855-63. doi: 10.1074/jbc.M111.232926. Epub 2011 May 5.
6
Acute promyelocytic leukaemia: novel insights into the mechanisms of cure.急性早幼粒细胞白血病:治愈机制的新见解。
Nat Rev Cancer. 2010 Nov;10(11):775-83. doi: 10.1038/nrc2943. Epub 2010 Oct 22.
7
A new oncoprotein catabolism pathway.
Blood. 2010 Sep 30;116(13):2200-1. doi: 10.1182/blood-2010-07-294025.
8
PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.PML/RARA 的氧化和砷结合引发了 As2O3 的抗白血病反应。
Cancer Cell. 2010 Jul 13;18(1):88-98. doi: 10.1016/j.ccr.2010.06.003.
9
Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.自噬有助于治疗诱导的 PML/RARA 癌蛋白降解。
Blood. 2010 Sep 30;116(13):2324-31. doi: 10.1182/blood-2010-01-261040. Epub 2010 Jun 23.
10
A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer.一种新型三氧化二砷纳米制剂,在乳腺癌小鼠模型中具有增强的治疗效果。
Clin Cancer Res. 2010 Jul 15;16(14):3607-17. doi: 10.1158/1078-0432.CCR-10-0068. Epub 2010 Jun 2.